Peter R. Kowey

23.6k total citations · 4 hit papers
368 papers, 13.0k citations indexed

About

Peter R. Kowey is a scholar working on Cardiology and Cardiovascular Medicine, Molecular Biology and Surgery. According to data from OpenAlex, Peter R. Kowey has authored 368 papers receiving a total of 13.0k indexed citations (citations by other indexed papers that have themselves been cited), including 332 papers in Cardiology and Cardiovascular Medicine, 41 papers in Molecular Biology and 24 papers in Surgery. Recurrent topics in Peter R. Kowey's work include Cardiac electrophysiology and arrhythmias (216 papers), Cardiac Arrhythmias and Treatments (193 papers) and Atrial Fibrillation Management and Outcomes (189 papers). Peter R. Kowey is often cited by papers focused on Cardiac electrophysiology and arrhythmias (216 papers), Cardiac Arrhythmias and Treatments (193 papers) and Atrial Fibrillation Management and Outcomes (189 papers). Peter R. Kowey collaborates with scholars based in United States, United Kingdom and Canada. Peter R. Kowey's co-authors include Bernard J. Gersh, Jonathan P. Piccini, Eric D. Peterson, Gregg C. Fonarow, Kenneth W. Mahaffey, Gan‐Xin Yan, Laine Thomas, Roger A. Marinchak, Seth J. Rials and Elaine M. Hylek and has published in prestigious journals such as New England Journal of Medicine, JAMA and Circulation.

In The Last Decade

Peter R. Kowey

357 papers receiving 12.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Calcium Antagonist vs a Non–Calcium Antagonist Hypertension Treatment Strategy for Patients With Coronary Artery Disease

2003 859 citations Peter R. Kowey et al. profile →
Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes

2016 353 citations Benjamin A. Steinberg, Peter Shrader et al. Journal of the American College of Cardiology profile →
The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation

2015 314 citations Laine Thomas, Elaine M. Hylek et al. profile →
Rationale and design of a large-scale, app-based study to identify cardiac arrhythmias using a smartwatch: The Apple Heart Study

2018 277 citations Mintu P. Turakhia, Peter R. Kowey et al. profile →

Peers

Peter R. Kowey

CCM

SURGE

RNMI

Michiel Rienstra Netherlands

Takeshi Yamashita Japan

Steven A. Lubitz United States

Katherine T. Murray United States

Sumeet S. Chugh United States

Lin Y. Chen United States

Paul Dorian Canada

Mina K. Chung United States

Dayi Hu China

John D. Horowitz Australia

Michiel Rienstra Netherlands

Peter R. Kowey

9.6k ×0.8

CCM

830 ×0.5

645 ×0.5

910 ×0.9

SURGE

827 ×1.1

RNMI

Citations per year, relative to Peter R. Kowey Peter R. Kowey (= 1×) peers Michiel Rienstra

Countries citing papers authored by Peter R. Kowey

Since Specialization

Citations

This map shows the geographic impact of Peter R. Kowey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter R. Kowey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter R. Kowey more than expected).

Fields of papers citing papers by Peter R. Kowey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter R. Kowey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter R. Kowey. The network helps show where Peter R. Kowey may publish in the future.

Co-authorship network of co-authors of Peter R. Kowey

This figure shows the co-authorship network connecting the top 25 collaborators of Peter R. Kowey. A scholar is included among the top collaborators of Peter R. Kowey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter R. Kowey. Peter R. Kowey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rienstra, Michiel, Aaf F.M. Kuijper, Sabine Eijsbouts, et al.. (2025). Flecainide acetate inhalation solution for cardioversion of recent-onset, symptomatic atrial fibrillation: results of the phase 3 RESTORE-1 trial. EP Europace. 27(4). 1 indexed citations

Singh, Jagmeet P., Mattias Wieloch, Carina Blomström‐Lundqvist, et al.. (2025). Dronedarone vs Sotalol Among Patients With Atrial Fibrillation. JACC. Clinical electrophysiology. 11(7). 1531–1542.

Fengsrud, Espen, Carina Blomström‐Lundqvist, A. John Camm, et al.. (2025). Antiarrhythmic drug use in atrial fibrillation among different European countries – as determined by a physician survey. IJC Heart & Vasculature. 59. 101709–101709.

Kowey, Peter R., et al.. (2024). Class IC Drugs in Cardiomyopathy. JACC. Clinical electrophysiology. 10(5). 854–856.

Stambler, Bruce S., Marco Alings, Paul Dorian, et al.. (2024). CE-482905-001 SELF-ADMINISTERED ETRIPAMIL NASAL SPRAY RAPIDLY TERMINATED SPONTANEOUS PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA (PSVT): ANALYSIS OF OPEN-LABEL TREATMENT IN THE RAPID STUDY. Heart Rhythm. 21(5). S32–S32.

Pundi, Krishna, Jun Fan, Shaum Kabadi, et al.. (2023). Dronedarone Versus Sotalol in Antiarrhythmic Drug–Naive Veterans With Atrial Fibrillation. Circulation Arrhythmia and Electrophysiology. 16(8). 456–467.

Camm, A. John, Jonathan P. Piccini, Marco Alings, et al.. (2023). Multicenter, Phase 2, Randomized Controlled Study of the Efficacy and Safety of Etripamil Nasal Spray for the Acute Reduction of Rapid Ventricular Rate in Patients With Symptomatic Atrial Fibrillation (ReVeRA-201). Circulation Arrhythmia and Electrophysiology. 16(12). 639–650. 5 indexed citations

Olshansky, Brian, Deepak L. Bhatt, Michael Miller, et al.. (2023). Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE‐IT. Journal of the American Heart Association. 12(5). e026756–e026756. 17 indexed citations

Carlisle, Matthew A., Peter Shrader, Marat Fudim, et al.. (2022). Residual stroke risk despite oral anticoagulation in patients with atrial fibrillation. Heart Rhythm O2. 3(6). 621–628. 3 indexed citations

10.

Verma, Atul, Rolf Wachter, Peter R. Kowey, et al.. (2019). Changes in Management Following Detection of Previously Unknown Atrial Fibrillation by an Insertable Cardiac Monitor (from the REVEAL AF Study). The American Journal of Cardiology. 124(6). 864–870. 4 indexed citations

11.

White, William B., Peter R. Kowey, Ulysses Diva, Mark Sostek, & Raj Tummala. (2018). Cardiovascular Safety of the Selective μ-Opioid Receptor Antagonist Naloxegol: A Novel Therapy for Opioid-Induced Constipation. Journal of Cardiovascular Pharmacology and Therapeutics. 23(4). 309–317. 10 indexed citations

12.

Steinberg, Benjamin A., Eric D. Peterson, Sunghee Kim, et al.. (2014). Use and Outcomes Associated With Bridging During Anticoagulation Interruptions in Patients With Atrial Fibrillation. Circulation. 131(5). 488–494. 149 indexed citations

13.

Liu, Tengxian, et al.. (2013). Abstract 10368: Early Afterdepolarization Alternans Manifests T Wave Alternans in Left Ventricular Hypertrophy. Circulation. 1 indexed citations

14.

Badri, Marwan, et al.. (2013). Abstract 14780: How Representative of the General Population Are the Cohorts Included in the Clinical Trials That Drive Our Guidelines?. Circulation. 128.

15.

Donohue, James F., Donald P. Tashkin, Gary T. Ferguson, et al.. (2013). Long-term Cardiovascular Safety of Aclidinium Bromide in Patients With COPD. CHEST Journal. 144(4). 716A–716A. 2 indexed citations

16.

Liu, Tengxian, Martin Traebert, Haisong Ju, et al.. (2012). Differentiating electrophysiological effects and cardiac safety of drugs based on the electrocardiogram: A blinded validation. Heart Rhythm. 9(10). 1706–1715. 16 indexed citations

17.

Piccini, Jonathan P., DaJuanicia N. Holmes, Winnie W. Nelson, et al.. (2011). Abstract 15347: Symptom Status and Treatment Strategy in Contemporary Management of Atrial Fibrillation: Findings From the ORBIT-AF Registry. Circulation. 124.

18.

Camm, A. John, Günter Breithardt, Harry J.G.M. Crijns, et al.. (2011). Real-Life Observations of Clinical Outcomes With Rhythm- and Rate-Control Therapies for Atrial Fibrillation. Journal of the American College of Cardiology. 58(5). 493–501. 128 indexed citations

19.

Cushing, Daniel J., et al.. (2009). PM101: A cyclodextrin-based intravenous formulation of amiodarone devoid of adverse hemodynamic effects. European Journal of Pharmacology. 607(1-3). 167–172. 23 indexed citations

20.

Podrid, Philip J., et al.. (1991). Comparative cost-effectiveness analysis of quinidine, procainamide and mexiletine. The American Journal of Cardiology. 68(17). 1662–1667. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact